RedHill Biopharma (RDHL) Total Current Liabilities (2014 - 2025)
RedHill Biopharma (RDHL) posted quarterly Total Current Liabilities of $19.2 million for Q4 2025, down 13.51% year-over-year from $22.2 million in Q4 2024, and down 13.76% quarter-over-quarter from $22.3 million in Q2 2025.
RedHill Biopharma (RDHL) Total Current Liabilities (2014 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has reported Total Current Liabilities for 12 consecutive years, with $19.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities fell 13.51% year-over-year to $19.2 million; the TTM figure through Dec 2025 stood at $19.2 million (down 13.51% YoY), while the FY2025 annual figure was $19.2 million, down 13.51% from the prior year.
- Total Current Liabilities fell to $19.2 million in Q4 2025 per RDHL's latest filing, from $22.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $197.5 million in Q4 2022 and bottomed at $19.2 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $65.8 million across 5 years, with a median of $25.2 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 142.36% — and 2023, when it plunged 89.88%.
- RedHill Biopharma's Total Current Liabilities stood at $81.5 million in 2021, then jumped by 142.36% to $197.5 million in 2022, then slumped by 89.88% to $20.0 million in 2023, then advanced by 11.21% to $22.2 million in 2024, then declined by 13.51% to $19.2 million in 2025.
- Business Quant data shows RDHL's Total Current Liabilities at $19.2 million in Q4 2025, $22.3 million in Q2 2025, and $22.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | 19.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.22 Mn |
| Jun 30, 2025 | 22.29 Mn |
| Dec 31, 2024 | 22.22 Mn |
| Jun 30, 2024 | 21.23 Mn |
| Dec 31, 2023 | 19.98 Mn |
| Jun 30, 2023 | 28.19 Mn |
| Dec 31, 2022 | 197.45 Mn |
| Jun 30, 2022 | 166.42 Mn |
| Dec 31, 2021 | 81.47 Mn |
| Jun 30, 2021 | 79.17 Mn |
| Dec 31, 2020 | 73.24 Mn |
| Jun 30, 2020 | 35.87 Mn |
| Dec 31, 2019 | 10.62 Mn |
| Jun 30, 2019 | 14.05 Mn |
| Dec 31, 2018 | 10.38 Mn |
| Jun 30, 2018 | 9.88 Mn |
| Mar 31, 2018 | 9.71 Mn |
| Dec 31, 2017 | 11.83 Mn |
| Dec 31, 2016 | 5.36 Mn |
| Mar 31, 2015 | 5.46 Mn |